What is ImmunityBio?
ImmunityBio operates as a vertically-integrated biotechnology enterprise dedicated to the development of advanced therapies and vaccines that harness the natural immune system. The company's core mission centers on creating durable, safe, and effective treatments for oncology and infectious diseases. Its flagship product, ANKTIVA, represents a significant milestone as an FDA-approved immunotherapy for non-muscle invasive bladder cancer, demonstrating the efficacy of its platform in activating natural killer cells and T cells. By integrating research, development, and manufacturing, the company maintains a competitive edge in the biopharma market, focusing on reducing the reliance on standard, high-toxicity chemotherapy protocols.
How much funding has ImmunityBio raised?
ImmunityBio has raised a total of $1.2B across 7 funding rounds:
Other Financing Round
$470M
Debt
$157M
Private Equity
$50M
Share Placement
$40M
Other Financing Round
$320M
Share Placement
$75M
Other Financing Round
$75M
Other Financing Round (2021): $470M with participation from Dr. Patrick Soon-Shiong and NantCapital
Debt (2022): $157M, investors not publicly disclosed
Private Equity (2023): $50M, investors not publicly disclosed
Share Placement (2023): $40M, investors not publicly disclosed
Other Financing Round (2024): $320M backed by Oberland Capital
Share Placement (2025): $75M, investors not publicly disclosed
Other Financing Round (2026): $75M led by Oberland Capital
Key Investors in ImmunityBio
Oberland Capital
Oberland Capital is a private investment firm focused on funding innovation in the global healthcare industry, managing approximately $3 billion in assets. The firm specializes in flexible investment structures tailored to meet the specific needs of its partners, offering a range of financing solutions including monetization of royalty streams and project-based financing.
Dr. Patrick Soon-Shiong
A prominent figure in the biotechnology sector, providing strategic capital and leadership to drive the development of next-generation immune-based therapies.
NantCapital
An investment firm focused on supporting high-growth companies in the life sciences and technology sectors, providing the necessary capital to scale complex medical innovations.
What's next for ImmunityBio?
Looking ahead, the strategic deployment of the $75M will likely focus on expanding the clinical reach of the company's immunotherapy platforms and optimizing its manufacturing capabilities. As the firm transitions into a more mature commercial phase, the focus will shift toward scaling the distribution of its approved therapies while simultaneously advancing its pipeline of potential cancer vaccines. The continued support from specialized healthcare investors suggests a long-term commitment to the company's vision of transforming the standard of care in oncology. Future growth will be contingent upon successful clinical trial outcomes and the ability to maintain a robust, scalable supply chain for its cell therapy products, ensuring that these innovative treatments remain accessible to a broader patient population.
See full ImmunityBio company page
